February 8, 2021 -- Seneca Therapeutics has expanded its research and development pipeline to include six new armed gene therapy/oncolytic constructs directed against important cancer targets and indications
The gene therapy technology uses Seneca Valley Virus (SVV) to exclusively target cancer cells with TEM 8 expression. Normal cells lack tumor endothelial marker-8 (TEM 8) expression and are therefore not infected by SVV-001 immunotherapies. Studies in multiple human tumor types indicate that TEM 8 expression is an adverse indicator of long-term survival and is associated with cancer metastasis. The company plans to develop combination products to be delivered intravenously. They include:
Each product has been or is being produced on Seneca's SVV platform. The company anticipates preclinical animal studies to begin in the second quarter of 2021.
The company also announced an SVV-001 armed construct program for the development of precision medicine constructs expressing patient-specific neoantigens.